에스티팜 Stock: price and insider trades · South Korea
No insider purchase over the last 90 days. The latest, by 임진석, was filed 30 Apr 2026.
에스티팜: what insiders have been doing
This page follows insider dealings at 에스티팜 as filed with DART (FSS), a company from the Health Care sector. In the past year (6 November 2025 to 6 November 2026), 10 filings came from 8 insiders.
The record shows 6 purchases on the open market worth €20.0M, made by 6 insiders, against 2 sales worth €577k by 2 insiders. The totals exclude 5 filings filed without an amount. Unlike grants, an open-market purchase is paid for by the insider, at the market price. One trade stands out by size: a purchase of €19.2M from 국민연금공단, disclosed on 1 April 2026, or 1.5% of market capitalisation. Among those who bought: 3 senior executives.
The data flag 1 purchase as part of a group of insiders buying within 30 days of each other. Purchases made close together by different insiders form what is called a cluster. The last insider purchase was made public on 30 April 2026, 194 days ago. Between a trade and the moment it shows up on DART (FSS), the median delay is 11 days. The shorter that gap, the sooner other investors can see what insiders have done.
For context, the typical company on the same exchange (median of 2,657 companies) published 7 filings over the same period, against 10 filings here. Over the whole record (from 2021), the tally stands at 7 purchases and 22 sales.
Elsewhere in the same sector, our signals recently picked up insider purchases at Dynavox Group AB and Vetoquinol SA. This summary is built from DART (FSS) disclosures alone and does not predict where the share price will go.
Who traded when
BuySaleSince the insiders bought
- -52.7%Entry ₩153,800 · Close 04 Nov 2026 ₩72,700
- -52.7%Entry ₩153,800 · Close 04 Nov 2026 ₩72,700
- -50.9%Entry ₩148,000 · Close 04 Nov 2026 ₩72,700
Entry is the close on the day after publication, the first price a reader could act on. Prices in the listing currency. Past moves are not a forecast.
Analyst consensus: bullish or bearish?
Analysts rate 에스티팜 Strong Buy (bullish), based on 9 analysts. Average price target: ₩147,778.
This score ranks the purchase within its own market. A position size is suggested only on the venues of the backtested strategy universe; elsewhere, signals stay on watch. Not investment advice.
Transparent value + quality ranking, distinct from the insider signal.
Financial data
as of FY 2025FY ended December 2025 · cache
- Other0DART
- Other0DART
- Other0DART
- Other0DART
- 6,551 shares0.045% mcap42.4% of flowKRXDART:20260430001577
- 5,000 sharesShareKRXDART:20260430001603Canonical exit: 23 Jul 2026 (T+90)
- 5,000 sharesShareKRXDART:20260430001595Canonical exit: 23 Jul 2026 (T+90)
- 4,650 sharesShareKRXDART:20260423000188Canonical exit: 2 Jul 2026 (T+90)
- 220,474 shares1.51% mcap100.0% of flowKRXDART:20260401004707Canonical exit: 20 May 2026 (T+90)
- 7,300 sharesShareKRXDART:20260330001552
- 1,000 sharesShareKRXDART:20260330001522
- 8,367 shares0.062% mcap57.6% of flowKRXDART:20260313000495Canonical exit: 3 Jun 2026 (T+90)
- ●Executives0DART
- 1,039,449 sharesKRXDART:20260102000167Canonical exit: 3 Mar 2026 (T+90)
- 59,161 sharesKRXDART:20241209000302
- 15,493 sharesKRXDART:20241030000243
- 949,856 sharesKRXDART:20240820000009
- ShareKRXDART:20240820000010
- 12,000 sharesKRXDART:20240702000329
- 64,076 sharesKRXDART:20240625000289
- ShareKRXDART:20240625000290
- ●Executives0DART
- 64,076 sharesKRXDART:20231206000406
- 64,076 sharesKRXDART:20231026000336
- 64,076 sharesKRXDART:20230905000262
25 of 40 declarations
About 에스티팜
Estipharm is a company specialized in the healthcare and pharmaceutical sector, listed on the XKRX market. It focuses on the development and manufacturing of innovative pharmaceutical products.
Recent ranked signals in the same sector
Purchases our model currently ranks for the recommendations list.
All recommendations
